Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
VANCOUVER – Cardiome Pharma Corp. (TSX:COM) is cutting 85 per cent of its workers as it eliminates all of those focused on internal research and certain support functions. The move comes after Merck terminated development efforts relating to the vernakalant oral program.
News from © iNFOnews.ca, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.